Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-19T08:42:49.214Z Has data issue: false hasContentIssue false
  • English
  • Français

A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients

Published online by Cambridge University Press:  16 April 2020

L. San ,
B. Arranz ,
I. Querejeta ,
S. Barrio ,
J. De la Gándara  and
V. Pérez
L. San*
Affiliation:
Hospital San Rafael, Passeig Vall d’Hebrón, 107–117, 08035Barcelona, Spain
B. Arranz
Affiliation:
Hospital San Rafael, Passeig Vall d’Hebrón, 107–117, 08035Barcelona, Spain
I. Querejeta
Affiliation:
Hospital de Donostia, San Sebastián, Spain
S. Barrio
Affiliation:
Hospital de San Juan de Dios, San Sebastián, Spain
J. De la Gándara
Affiliation:
Hospital General Yagüe, Burgos, Spain
V. Pérez
Affiliation:
Hospital de Sant Pau, Barcelona, Spain
*
*Corresponding author. E-mail address: [email protected] (L. San).
Get access

Abstract

Background

We conducted a naturalistic, multicenter, 24-hour, nonrandomized, observational study describing for the first time the effectiveness and safety of intramuscular (IM) olanzapine to control agitation and aggression in “real world” patients with psychosis. The data thus obtained was compared with that reported from randomized double-blind clinical trials.

Method

92 patients attending psychiatric emergency settings were enrolled. The study subjects were 44 male and 48 female patients with a mean age of 36.5 ± 12 years and DSM-IV-TR diagnoses of schizophrenia (48.9%), psychotic disorder not specified (23.9%) or bipolar disorder (27.2%). 10 mg IM olanzapine was administered to all patients. An optional second injection was permitted ≥ 2 hours later in line with hospital policy. Evaluations (PANSS-EC and CGI-S) were performed at baseline and 2 and 24 hours following the IM injection.

Results

Two hours after IM olanzapine was administered, a mean decrease of –9.6 in the PANSS-EC from a baseline score of 26.5 was recorded. At the 24-hour endpoint a statistically and clinically significant reduction in the PANSS-EC scores (11.6 ± 5.3) was observed as compared with values at study entry (26.5 ± 5.9) and at 2 hours endpoint (16.9 ± 9.3), which represent a mean decrease of –14.9 and –5.3, respectively.

Conclusion

The present naturalistic study provides naturalistic data on the effectiveness of IM olanzapine in the treatment of acute agitation in patients with schizophrenia or bipolar mania that is in line the data obtained in randomized double-blind clinical trials.

Keywords

Atypical antipsychoticsIntramuscularSchizophreniaAgitationOlanzapine
Type
Original article
Information
European Psychiatry , Volume 21 , Issue 8 , December 2006 , pp. 539 - 543
Copyright
Copyright © Elsevier Masson SAS 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Beaudoin, M.N., Hodgins, S., Lavoie, F.Homicide, schizophrenia and substance abuse and dependency Can. J. Psychiatry 1993; 38:541.CrossRefGoogle ScholarPubMed
Breier, A., Meeham, K., Birkett, M., David, S., Ferchland, I., Sutton, V.et al.A double-blind, placebo-controlled dose–response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia Arch. Gen. Psychiatry 2002; 59:441–448.CrossRefGoogle Scholar
Citrome, L.New treatments for agitation Psychiatr. Q. 75(3)2004 197–213.CrossRefGoogle ScholarPubMed
Citrome, L., Volavka, J.Psychiatric disorders and violence. Tardiff, K., Medical Management of the Violent Patient. Clinical Assessment and Therapy New York: Marcel Dekker, Inc; 1999. 125–152.Google Scholar
Guy, W.ECDEU Assessment Manual for Psychopharmacology. US Department of Health and Welfare Washington DC 1976; 338:534–537.Google Scholar
Humphreys, M.S., Johnstone, E.C., Mac Millan, J.F., Taylor, P.J.Dangerous behavior preceding first admission for schizophrenia Br. J. Psychiatry 1992; 161:501.CrossRefGoogle Scholar
Kapur, S., Arenovich, T., Agid, O., Zipursky, R., Lindborg, S., Jones, B.Evidence of antipsychotic effects within the first 24 hours of treatment Am. J. Psychiatry 2005; 162:939–946.CrossRefGoogle ScholarPubMed
Kay, S.R., Sevy, S.Pyramidical model of schizophrenia Schizophr. Bull. 1990; 16:537–545.CrossRefGoogle ScholarPubMed
Kunik, M.E., Yudofsky, S.C., Silver, J.M., Hales, R.E.Pharmacologic approach to management of agitation associated with dementia J. Clin. Psychiatry 55(Suppl)1994 13–17.Google ScholarPubMed
Meehan, K., Zhang, F., David, S., Tohen, M., Janicak, P., Small, J.et al.A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania J. Clin. Psychopharmacol. 2001; 21:389–397.CrossRefGoogle ScholarPubMed
NICE. Violence: The short-term management of disturbed/violent behaviour in in-patient psychiatric settings and emergency departments. Clinical Guideline 25 London NHS; 2005.Google Scholar
Pilowsky, L.S., Ring, H., Shine, P.J., Battersby, M., Lader, M.Rapid tranquillisation. A survey of emergency prescribing in a general psychiatric hospital Br. J. Psychiatry 1992; 160:831–835.CrossRefGoogle Scholar
San, L., Arranz, B., Escobar, R.Pharmacological management of acutely agitated schizophrenic patients Curr. Pharm. Des. 11(19)2005 2471–2477.CrossRefGoogle ScholarPubMed
Sebastian, C.S., Glazer, W., Buckley, P.F.Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia Curr. Med. Chem. 11(3)2004 329–342.CrossRefGoogle ScholarPubMed
Tulloch, K.J., Zed, P.J.Intramuscular olanzapine in the management of acute agitation Ann. Pharmacother. 2004; 38:2128–2135.CrossRefGoogle ScholarPubMed
Turczynski, J., Bidzan, L., Staszewska-Malys, E.Olanzapine in the treatment of agitation in hospitalised patients with schizophrenia and schizoaffective and schizofreniphorm disorders Med. Sci. Monit. 10(5)2004 PI74–PI80.Google Scholar
Verdoux, H., Bégaud, B.Pharmaco-epidemiology: what do (and don’t) we know about utilisation and impact of psychotropic medications in real-life conditions? Br. J. Psychiatry 2004; 185:93–94.CrossRefGoogle ScholarPubMed
Virkkunen, M.Observations on violence in schizophrenia Acta Psychiatr. Scand. 1974; 50:145.Google Scholar
Wagstaff, A.J., Easton, J., Scott, L.J.Intramuscular olanzapine. A review of its use in the management of acute agitation CNS Drugs 19(2)2005 147–164.CrossRefGoogle ScholarPubMed
Wright, P., Birkett, M., David, S.R., Meeham, K., Ferchland, I., Alaka, K.et al.Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia Am. J. Psychiatry 2001; 7:1149–1151.CrossRefGoogle Scholar
Yildiz, A., Sachs, G.S., Turgay, A.Pharmacological management of agitation in emergency settings Emerg. Med. J. 2003; 20:339–346.CrossRefGoogle ScholarPubMed
Yudofsky, S.C., Silver, J.M., Hales, R.E.Treatment of Agitation and Aggression. Schaltzberg, A.F., Nemeroff, C.B., The American Psychiatric Press Textbook of Psychopharmacology. Washington DC: American Psychiatric Press; 1998. 881–900.Google Scholar
Submit a response

Comments

No Comments have been published for this article.